{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T20:03:13Z","timestamp":1773172993648,"version":"3.50.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1016\/j.ahj.2013.06.024","type":"journal-article","created":{"date-parts":[[2013,9,17]],"date-time":"2013-09-17T04:03:25Z","timestamp":1379390605000},"page":"654-661.e6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Rationale, design, and baseline characteristics of the Study assessInG the morbidity-mortality beNefits of the If inhibitor ivabradine in patients with coronarY artery disease (SIGNIFY trial): A randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease without clinical heart failure"],"prefix":"10.1016","volume":"166","clinical-trial-number":[{"clinical-trial-number":"isrctn61576291","registry":"10.18810\/isrctn"}],"author":[{"given":"Kim","family":"Fox","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian","family":"Ford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe Gabriel","family":"Steg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Claude","family":"Tardif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michal","family":"Tendera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2013.06.024_bb0005","first-page":"e18","article-title":"Heart disease and stroke statistics\u20142011 update: a report from the American Heart Association","volume":"123","author":"Roger","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2013.06.024_bb0010","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/j.jacc.2007.05.056","article-title":"Coronary heart disease mortality among young adults in the U.S. from 1980 through 2002: concealed leveling of mortality rates","volume":"50","author":"Ford","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2013.06.024_bb0015","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.jacc.2007.04.079","article-title":"Resting heart rate in cardiovascular disease","volume":"50","author":"Fox","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2013.06.024_bb0020","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/nrcardio.2011.58","article-title":"Heart rate: a forgotten link in coronary artery disease?","volume":"8","author":"Fox","year":"2011","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.ahj.2013.06.024_bb0025","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1093\/eurheartj\/ehi190","article-title":"Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease","volume":"26","author":"Diaz","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2013.06.024_bb0030","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/0002-8703(87)90666-1","article-title":"Heart rate and cardiovascular mortality: the Framingham Study","volume":"113","author":"Kannel","year":"1987","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2013.06.024_bb0035","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/S0140-6736(10)61259-7","article-title":"Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial","volume":"376","author":"B\u00f6hm","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2013.06.024_bb0040","first-page":"e354","volume":"126","author":"Fihn","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2013.06.024_bb0045","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1161\/hc3801.096325","article-title":"Left ventricular muscle mass and elevated heart rate are associated with coronary plaque disruption","volume":"104","author":"Heidland","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2013.06.024_bb0050","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1161\/CIRCULATIONAHA.112.096438","article-title":"Prediction of progression of coronary artery disease and clinical outcomes using vascular profiling of endothelial shear stress and arterial plaque characteristics: the PREDICTION Study","volume":"126","author":"Stone","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2013.06.024_bb0055","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(08)61171-X","article-title":"Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial","volume":"372","author":"Fox","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2013.06.024_bb0060","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1093\/eurheartj\/ehn123","article-title":"Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil-SR\/trandolapril STudy (INVEST)","volume":"29","author":"Kolloch","year":"2008","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2013.06.024_bb0065","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0735-1097(02)02848-6","volume":"41","author":"Gibbons","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2013.06.024_bb0070","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.2165\/00003495-200464160-00003","article-title":"Heart rate lowering by specific and selective If current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease","volume":"64","author":"DiFrancesco","year":"2004","journal-title":"Drugs"},{"key":"10.1016\/j.ahj.2013.06.024_bb0075","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1097\/00005344-200311000-00016","article-title":"Anti-ischemic effects of ivabradine, a selective heart rate-reducing agent, in exercise-induced myocardial ischemia in pigs","volume":"42","author":"Vilaine","year":"2003","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.ahj.2013.06.024_bb0080","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1161\/01.CIR.0000118464.48959.1C","article-title":"Long-term heart rate reduction induced by the selective I(f) current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure","volume":"109","author":"Mulder","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2013.06.024_bb0085","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0022-3565(25)12114-9","article-title":"Coronary and hemodynamic effects of S 16257, a new bradycardic agent, in resting and exercising conscious dogs","volume":"275","author":"Simon","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.ahj.2013.06.024_bb0090","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1093\/eurheartj\/ehn571","article-title":"Efficacy of the If current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4 month, randomized, placebo-controlled trial","volume":"30","author":"Tardif","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2013.06.024_bb0095","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1093\/eurheartj\/ehi586","article-title":"Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina","volume":"26","author":"Tardif","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2013.06.024_bb0100","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","article-title":"Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled trial","volume":"376","author":"Swedberg","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2013.06.024_bb0105","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1093\/eurheartj\/eht101","article-title":"Effect of ivabradine in patients with left-ventricular systolic dysfunction: a pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials","volume":"34","author":"Fox","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2013.06.024_bb0110","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S0140-6736(08)61170-8","article-title":"Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial","volume":"372","author":"Fox","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2013.06.024_bb0115","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1093\/eurheartj\/ehp358","article-title":"Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial","volume":"30","author":"Fox","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2013.06.024_bb0120","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0140-6736(09)60330-5","article-title":"Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries","volume":"373","author":"Kotseva","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2013.06.024_bb0125","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1001\/jama.2011.601","article-title":"Patterns and intensity of medical therapy in patients undergoing percutaneous coronary intervention","volume":"305","author":"Borden","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2013.06.024_bb0130","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1001\/jama.295.2.180","article-title":"International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis","volume":"295","author":"Bhatt","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2013.06.024_bb0135","doi-asserted-by":"crossref","first-page":"e36284","DOI":"10.1371\/journal.pone.0036284","article-title":"Heart rate and use of beta-blockers in stable outpatients with coronary artery disease","volume":"7","author":"Steg","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ahj.2013.06.024_bb0140","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1093\/eurheartj\/ehi171","article-title":"The clinical characteristics and investigations planned in patients with stable angina presenting to cardiologists in Europe: from the Euro Heart Survey of Stable Angina","volume":"26","author":"Daly","year":"2005","journal-title":"Eur Heart J"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870313004456?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870313004456?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T05:51:24Z","timestamp":1757569884000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870313004456"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["S0002870313004456"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2013.06.024","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rationale, design, and baseline characteristics of the Study assessInG the morbidity-mortality beNefits of the If inhibitor ivabradine in patients with coronarY artery disease (SIGNIFY trial): A randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease without clinical heart failure","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2013.06.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}